Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;14(4):900-903.
doi: 10.1007/s13193-023-01808-7. Epub 2023 Sep 6.

Syringocystadenocarcinoma Papilliferum of Thigh-a Rare Cutaneous Malignancy with Unusual Histology and Clinical Presentation

Sudipta Naskar  1 , Archana Manohar  2 , Srivatsa H G  3 , Divya V  2 , Rekha V Kumar  2 , B S Srinath  3
Affiliations

Syringocystadenocarcinoma Papilliferum of Thigh-a Rare Cutaneous Malignancy with Unusual Histology and Clinical Presentation

Sudipta Naskar et al. Indian J Surg Oncol. 2023 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A and D T1-weighted MRI of pelvis exhibiting exophytic lesion involving the upper thigh (white arrow) and an enlarged inguinal lymph nodes (black arrow). B FLAIR and C T2-weighted MRI—both show hyperintense exophytic lesion involving the upper thigh (white arrow) and also hyperintense enlarged inguinal lymph node (black arrow). E Macroscopic image showing exophytic grey-white lesion
Fig. 2
Fig. 2
A Benign syringocystadenoma papilliferum component, H&E × 40. B Benign syringocystadenoma papilliferum component (red arrow) with malignant syringocystadenocarcinoma component (green arrow), H&E × 40. C Invasive squamous cell carcinoma component, H&E × 100. D Invasive non-squamous cell carcinoma component, H&E × 100. E Malignant syringocystadenocarcinoma component with comedo necrosis, H&E × 40. F Lymph nodal metastasis, H&E × 40. G IHC for GCDFP-15 shows moderate to strong cytoplasmic expression, revealing the apocrine origin of the tumour, × 100 magnification. H p63 IHC, × 40 magnification: the squamous component shows strong nuclear expression (green arrow) while the non-squamous component (beneath red arrow) is negative for p63. I CK7 IHC: strong membranous staining, × 40 magnification. J CD117 IHC showing moderate to strong patchy expression, × 40 magnification. K p63 IHC: the malignant squamous component show strong and diffuse nuclear expression, × 100 magnification. L p63 highlights the basal layer in the benign syringocystadenoma papilliferum component, × 40 magnification
See this image and copyright information in PMC

References

    1. Halsey JN, Faith EF, Logan SJ, et al. Syringocystadenocarcinoma papilliferum in a fifteen-year-old girl: a case report and review of the literature. Case Rep Dermatol Med. 2022;2022:8076649. - PMC - PubMed
    1. Shankar S, Kumarguru B, Arathi C, Ramaswamy A, Prashanth R. Syringocystadenocarcinoma papilliferum—an uncommon malignant adnexal neoplasm at an unusual location. J Clin of Diagn Res. 2019;13(7):ED01–ED04.
    1. Zhang Y, Kong YY, Cai X, Shen XX, Kong JC. Syringocystadenocarcinoma papilliferum: clinicopathologic analysis of 10 cases. J Cutan Pathol. 2017;44(6):538–543. doi: 10.1111/cup.12934. - DOI - PubMed
    1. Seco Navedo MA, Fresno Forcelledo M, Orduña Domingo A, Junco Petrement P, Soler Sanchez T. Syringocytadenoma papilliferum with malignant evolution. Presentation of a case. Ann Dermatol Venereol. 1982;109(8):685–689. - PubMed
    1. Parekh V, Guerrero CE, Knapp CF, Elmets CA, McKay KM. A histological snapshot of hypothetical multistep progression from nevus sebaceus to invasive syringocystadenocarcinoma papilliferum. Am J Dermatopathol. 2016;38(1):56–62. doi: 10.1097/DAD.0000000000000370. - DOI - PubMed

LinkOut - more resources